Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11365-11380

  Zhang, Xuan ^a   Cheng, Lihua ^a   Minn, Kay ^a   Madan, Rashna ^a   Godwin, Andrew K ^a   Shridhar, Viji ^b   Chien, Jeremy ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOHEXIMIDE; DACTINOMYCIN; FORKHEAD BOX M1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; MESSENGER RNA; NUTLIN 3; PROTEIN P53; SHORT HAIRPIN RNA; THIOSTREPTON; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FOXM1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL DESTRUCTION; CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PROTEIN EXPRESSION; RNA DEGRADATION; RNA STABILITY; TP53 GENE; UPREGULATION; WILD TYPE; ANIMAL; APOPTOSIS; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NUDE MOUSE; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEK293 CELLS; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUTATION; OVARIAN NEOPLASMS; PIPERAZINES; THIOSTREPTON; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84917689177     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2497     Document Type: Article

References (60)

1. Halasi M, Gartel AL. Targeting FOXM1 in cancer. Biochemical pharmacology. 2013; 85:644-652.
2. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
3. Yao KM, Sha M, Lu Z, Wong GG. Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. The Journal of biological chemistry. 1997; 272:19827-19836.
4. Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, Tindall DJ, Chen J. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nature cell biology. 2008; 10:1076-1082.
5. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nature cell biology. 2005; 7:126-136.
6. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T, Costa RH. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Molecular and cellular biology. 2005; 25:10875-10894.
7. Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer research. 2005; 65:5181-5189.
8. Huynh KM, Soh JW, Dash R, Sarkar D, Fisher PB, Kang D. FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells. Journal of cellular physiology. 2011; 226:194-204.
9. Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochimica et biophysica acta. 2007; 1775:92-102.
10. Korver W, Roose J, Clevers H. The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic acids research. 1997; 25:1715-1719.
11. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Downregulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer research. 2007; 67:8293-8300.
12. Barsotti AM, Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene. 2009; 28: 4295-4305.
13. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, Hajji N, Lam EW. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Molecular cancer therapeutics. 2011; 10:1046-1058.
14. Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, Fan D, Nie Y, Wu K. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. Journal of hepatology. 2012.
15. Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM, Huang HY, Chen CM, Liu HL, Huang CY. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 2009; 28:2723-2737.
16. Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K. Dysregulated expression of FOXM1 isoforms drive progression of pancreatic cancer. Cancer research. 2013.
17. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer research. 2010; 70:5054-5063.
18. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC, et al. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. International journal of oncology. 2009; 35:57-68.
19. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS, Lam EW. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Molecular cancer research: MCR. 2010; 8:24-34.
20. McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM, Polychronis A, Coombes RC, Lam EW. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular cancer therapeutics. 2009; 8:582-591.
21. Yau C, Wang Y, Zhang Y, Foekens JA, Benz CC. Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrinedependent breast cancers. Breast cancer research and treatment. 2011; 126:803-810.
22. Llaurado M, Majem B, Castellvi J, Cabrera S, Gil-Moreno A, Reventos J, Ruiz A. Analysis of Gene Expression Regulated by the ETV5 Transcription Factor in OV90 Ovarian Cancer Cells Identifies FOXM1 Overexpression in Ovarian Cancer. Molecular cancer research: MCR. 2012; 10:914-924.
23. Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene. 2010; 29:2983-2995.
24. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, Yao KM. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. Journal of cell science. 2005; 118:795-806.
25. Xia LM, Huang WJ, Wang B, Liu M, Zhang Q, Yan W, Zhu Q, Luo M, Zhou ZZ, Tian DA. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. Journal of cellular biochemistry. 2009; 106: 247-256.
26. Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, Moore DD, Trumpp A. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology. 2008; 48:1302-1311.
27. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocrine-related cancer. 2006; 13: 293-325.
28. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature reviews Drug discovery. 2008; 7:979-987.
29. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cellular and molecular life sciences: CMLS. 1999; 55:48-63.
30. Maslon MM, Hupp TR. Drug discovery and mutant p53. Trends in cell biology. 2010; 20:542-555.
31. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature reviews Cancer. 2009; 9:701-713.
32. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Seminars in cancer biology. 2003; 13: 49-58.
33. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle. 2004; 3:419-421.
34. Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. p53 dynamics control cell fate. Science. 2012; 336:1440-1444.
35. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:1888-1893.
36. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR. Cosmic 2005. British journal of cancer. 2006; 94:318-322.
37. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nature communications. 2013; 4:2126.
38. Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD. Genomic analysis of genetic heterogeneity and evolution in highgrade serous ovarian carcinoma. Oncogene. 2010; 29: 4905-4913.
39. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids research. 2011; 39:D945-950.
40. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303:844-848.
41. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387:299-303.
42. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS letters. 1997; 420:25-27.
43. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, Lam EW. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Molecular cancer therapeutics. 2008; 7:2022-2032.
44. Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nature chemistry. 2011; 3:725-731.
45. Halasi M, Gartel AL. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle. 2009; 8: 1966-1967.
46. Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5:1905-1917.
47. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502:333-339.
48. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer cell. 2014; 25:304-317.
49. Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K. Dysregulated Expression of FOXM1 Isoforms Drives Progression of Pancreatic Cancer. Cancer research. 2013; 73:3987-3996.
50. Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, Yu W. miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS letters. 2012; 586:3761-3765.
51. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, Chien CH, Wu MC, Huang CY, Tsou AP, Huang HD. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic acids research. 2011; 39:D163-169.
52. Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PloS one. 2009; 4:e6593.
53. Gartel AL. Paradoxical inhibition of cellular protein expression by proteasome inhibitors. BioMol Concepts. 2012; 3:593-595.
54. Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell death and differentiation. 2013; 20:898-909.
55. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, Califano A, Abate-Shen C. Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy. Cancer cell. 2014; 25: 638-651.
56. Park HJ, Gusarova G, Wang Z, Carr JR, Li J, Kim KH, Qiu J, Park YD, Williamson PR, Hay N, Tyner AL, Lau LF, Costa RH, Raychaudhuri P. Deregulation of FoxM1b leads to tumour metastasis. EMBO molecular medicine. 2011; 3:21-34.
57. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer research. 2006; 66:3169-3176.
58. Siegel MR, Sisler HD. Inhibition of Protein Synthesis in Vitro by Cycloheximide. Nature. 1963; 200:675-676.
59. Bensaude O. Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity? Transcription. 2011; 2:103-108.
60. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55.